دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Fresh Assault on Insurance Coverage Mandates
Michelle M. Mello, J.D., Ph.D., and Anne Joseph O’Connell, J.D., Ph.D.
doi : 10.1056/NEJMp2213835
Evidence over Politics — The U.S. Preventive Services Task Force
Barron H. Lerner, M.D., Ph.D., and Graham Curtiss-Rowlands, M.A.
doi : 10.1056/NEJMp2212725
Lecanemab in Early Alzheimer’s Disease
Christopher H. van Dyck, M.D., Chad J. Swanson, Ph.D., Paul Aisen, M.D., Randall J. Bateman, M.D., Christopher Chen, B.M., B.Ch., Michelle Gee, Ph.D., Michio Kanekiyo, M.S., David Li, Ph.D., Larisa Reyderman, Ph.D., Sharon Cohen, M.D., Lutz Froelich, M.D., Ph.D., Sadao Katayama, M.D.,
doi : 10.1056/NEJMoa2212948
Trial of an Intervention to Improve Acute Heart Failure Outcomes
Douglas S. Lee, M.D., Ph.D., Sharon E. Straus, M.D., Michael E. Farkouh, M.D., Peter C. Austin, Ph.D., Monica Taljaard, Ph.D., Alice Chong, B.Sc., Christine Fahim, Ph.D., Stephanie Poon, M.D., Peter Cram, M.D., Stuart Smith, M.D., Robert S. McKelvie, M.D., Ph.D., Liane Porepa, M.D.,
doi : 10.1056/NEJMoa2211680
Patients with acute heart failure are frequently or systematically hospitalized, often because the risk of adverse events is uncertain and the options for rapid follow-up are inadequate. Whether the use of a strategy to support clinicians in making decisions about discharging or admitting patients, coupled with rapid follow-up in an outpatient clinic, would affect outcomes remains uncertain.
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
John H. Strickler, M.D., Hironaga Satake, M.D., Ph.D., Thomas J. George, M.D., Rona Yaeger, M.D., Antoine Hollebecque, M.D., Ignacio Garrido-Laguna, M.D., Ph.D., Martin Schuler, M.D., Timothy F. Burns, M.D., Ph.D., Andrew L. Coveler, M.D., Gerald S. Falchook, M.D., Mark Vincent, M.D., Yu Sunakawa, M.D., Ph.D.,
doi : 10.1056/NEJMoa2208470
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Rona Yaeger, M.D., Jared Weiss, M.D., Meredith S. Pelster, M.D., Alexander I. Spira, M.D., Ph.D., Minal Barve, M.D., Sai-Hong I. Ou, M.D., Ph.D., Ticiana A. Leal, M.D., Tanios S. Bekaii-Saab, M.D., Cloud P. Paweletz, Ph.D., Grace A. Heavey, B.A., James G. Christensen, Ph.D., Karen Velastegui, B.Sc.,
doi : 10.1056/NEJMoa2212419
Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical studies suggest that combining a KRAS G12C inhibitor with an epidermal growth factor receptor antibody could be an effective clinical strategy.
New Approaches to Chronic Hepatitis B
Geoffrey Dusheiko, M.D., Kosh Agarwal, M.D., and Mala K. Maini, M.D., Ph.D.
doi : 10.1056/NEJMra2211764
Locomotor Brachii Sign in Aortic Regurgitation
Gonzalo Barge-Caballero, M.D., Ph.D., and Cayetana Barbeito-Caamaño, M.D.
doi : 10.1056/NEJMicm2206470
A Stormy Heart
Allison Kratka, M.D., Usha B. Tedrow, M.D., Richard N. Mitchell, M.D., Ph.D., Amy L. Miller, M.D., Ph.D., and Joseph Loscalzo, M.D., Ph.D.
doi : 10.1056/NEJMcps2116690
Moving the Needle on Alzheimer’s Disease with an Anti-Oligomer Antibody
Sam Gandy, M.D., Ph.D., and Michelle E. Ehrlich, M.D.
doi : 10.1056/NEJMe2214981
More COACHing Needed to Optimize Care after Heart Failure Hospitalization
Parag Goyal, M.D., and Evelyn M. Horn, M.D.
doi : 10.1056/NEJMe2214117
Audio Interview: The Expanding Arsenal of Oral Agents to Treat Covid-19
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2300069
Protecting the Public Health with the Inflation Reduction Act — Provisions Affecting Climate Change and Its Health Effects
Robert L. Glicksman, J.D.
doi : 10.1056/NEJMms2212981
